TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02160158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine ER (fasted)
Description: Commercial Fesoterodine ER 4 mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR3 (fasted)
Description: Fesoterodine SR3 4 mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR3 (fed)
Description: Fesoterodine SR3 4 mg (single dose) with high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine ER (fed)
Description: Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR3 (sprinkle)
Description: Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine ER (fasted)
Description: Commercial Fesoterodine ER 4 mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR4 (fasted)
Description: Fesoterodine SR4 4 mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR4 (fed)
Description: Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine ER (fed)
Description: Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR4 (sprinkle)
Description: Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
Study: NCT04051047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy and blood draw
Description: As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
Study: NCT04600674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: DCC performed at 60 sec after birth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cord clamping
Description: ECC performed at 15 sec after birth
Study: NCT02440477

Intervention type: OTHER
Intervention: clinical shoulder tests
Description: Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer

Intervention type: OTHER
Intervention: clinical shoulder tests
Description: Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
Study: NCT00621829

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA enriched fish oils
Description: Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA enriched fish oils
Description: Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
Study: NCT02609945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolmitriptan
Description: Oral Tablet and Nasal Spray
Study: NCT02469454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early insertion
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional insertion
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
Study: NCT02429895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: Injection
Study: NCT03382938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: WOUND INFILTRATION IN CESAREAN SECTION
Study: NCT02609945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-427 (zolmitriptan inhalation powder),
Description: Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
Study: NCT03382938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: WOUND INFILTRATION IN CESAREAN SECTION

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine - Ropivacaine
Description: WOUND INFILTRATION IN CESAREAN SECTION

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% saline
Description: placebo WOUND INFILTRATION IN CESAREAN SECTION
Study: NCT03337074

Intervention type: OTHER
Intervention: Questionnaire, semen sample, fasting blood sample
Description: Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.

Intervention type: OTHER
Intervention: Questionnaire, semen sample, fasting blood sample
Description: Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.

Intervention type: OTHER
Intervention: Questionnaire
Description: Participants are asked to complete a questionnaire.

Intervention type: OTHER
Intervention: Questionnaire, fasting blood sample
Description: Participants are asked to complete a questionnaire and provide a fasting blood sample.
Study: NCT00310531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menostar (Estradiol, BAY86-5435)
Description: Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: Raloxifene tbl. (60 mg/day)
Study: NCT02484963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04358653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention exercise program
Description: The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
Study: NCT03566251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional mobility
Description: Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk position sense
Description: Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
Study: NCT01321268

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)
Description: oral, twice daily in morning and evening for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Viatmin E
Description: oral, twice daily in morning and evening for 6 months
Study: NCT01846611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: 30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
Study: NCT03962127

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01162967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Standard dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Study: NCT00702741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondrogen
Description: Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondrogen
Description: Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection of Hyaluronan
Study: NCT02584257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo Lupin albuterol HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo Lupin albuterol HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo Lupin albuterol HFA MDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Lupin albuterol HFA MDI
Study: NCT01846611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL
Description: 50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
Study: NCT02743650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
Study: NCT01844609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Study Journal Club
Description: This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Journal Club
Description: This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
Study: NCT01253759

Intervention type: PROCEDURE
Intervention: TTT + ICG-based PDT
Study: NCT01505868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02333695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Magnetic Stimulation
Description: Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
Study: NCT00867451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: A structured sleep protocol is taught to parents, use of a white noise generator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: A structured sleep protocol is taught to parents, use of a white noise generator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks
Study: NCT03195088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 473494
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 473494
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study: NCT00935844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-901
Description: This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2.
Study: NCT00947479

Intervention type: OTHER
Group type: OTHER
Intervention: continuous positive airway pressure (CPAP)
Description: After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
Study: NCT03272607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing opportunities
Description: An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
Study: NCT00866684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
Study: NCT04052594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475766 - IV
Description: Administered IV
Study: NCT01895855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200
Description: Single dose; liquid suspension after reconstitution with buffer; 5x10\^8

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03038633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Medical Food
Description: This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Medical Food
Description: This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Medical Food
Description: This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Medical Food
Description: This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
Study: NCT01387347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin beta 4
Description: A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.